Therapeutic antibodies under development for SARS-CoV-2.

Ma, Zetong; Zhu, MengMei; Zhang, Shuyi; Qian, Kewen; Wang, Chuqi; Fu, Wenyan; Lei, Changhai; Hu, Shi

Ma, Zetong; Zhu, MengMei; Zhang, Shuyi; Qian, Kewen; Wang, Chuqi; Fu, Wenyan; Lei, Changhai; Hu, Shi.

Afiliação

Ma Z; Department of Biophysics College of Basic Medical Sciences Second Military Medical University Shanghai China.
Zhu M; Department of Biophysics College of Basic Medical Sciences Second Military Medical University Shanghai China.
Zhang S; Team SMMU-China of the International Genetically Engineered Machine (iGEM) competition Department of Biophysics Second Military Medical University Shanghai China.
Qian K; Department of Biophysics College of Basic Medical Sciences Second Military Medical University Shanghai China.
Wang C; Department of Biophysics College of Basic Medical Sciences Second Military Medical University Shanghai China.
Fu W; Team SMMU-China of the International Genetically Engineered Machine (iGEM) competition Department of Biophysics Second Military Medical University Shanghai China.
Lei C; Department of Biophysics College of Basic Medical Sciences Second Military Medical University Shanghai China.
Hu S; Team SMMU-China of the International Genetically Engineered Machine (iGEM) competition Department of Biophysics Second Military Medical University Shanghai China.

View (Beijing) ; 3(2): 20200178, 2022 Mar.

Article em En | MEDLINE | ID: mdl-34766160

Palavras-chave

Iglike proteins; SARSCoV; SARSCoV2; neutralization

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: View (Beijing) Ano de publicação: 2022 Tipo de documento: Article